You are here: Industry Insights > Sandoz

News List

Sandoz axes filing of US Rituxan biosimilar pharmaphorum
December 14, 2018
Sandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved in the US.
FDA clears Sandoz, Pear Therapeutics' prescription digital therapeutic for opioid use disorder firstwordpharma
December 11, 2018
Novartis' Sandoz unit and Pear Therapeutics announced Monday that the FDA cleared reSET-O, marking the first FDA-cleared prescription digital therapeutic for patients with opioid use disorder.
FDA clears Sandoz, Pear Therapeutics' prescription digital therapeutic for opioid use disorder firstwordpharma
December 11, 2018
Novartis' Sandoz unit and Pear Therapeutics announced Monday that the FDA cleared reSET-O, marking the first FDA-cleared prescription digital therapeutic for patients with opioid use disorder.
EC approves Sandoz’s biosimilar Ziextenzo for febrile neutropenia pharmaceutical
November 29, 2018
Novartis unit Sandoz has received marketing authorisation from the European Commission (EC) for biosimilar Ziextenzo (pegfilgrastim).......
Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz pharmafile
November 28, 2018
The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s Neulasta, the company has announced.
NHS set to save record £300 million on highest drug spend contractpharma
November 28, 2018
The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug.
Sandoz Receives Eighth EC Approval for Biosimilar with Ziextenzo americanpharmaceuticalreview
November 28, 2018
Sandoz announced that the European Commission (EC) granted marketing authorization for biosimilar Ziextenzo (pegfilgrastim).Ziextenzo is indicated to reduce the duration......
Sandoz to focus on more lucrative markets biospectrumasia
November 19, 2018
Sandoz’s strategy to prioritize other more profitable markets for Rixathon will benefit the company in the long term. mage credit- contractpharma.com
Sandoz to focus on more lucrative markets biospectrum
November 16, 2018
Sandoz’s strategy to prioritize other more profitable markets for Rixathon will benefit the company in the long term.
FDA updates on angiotensin II receptor blocker (ARB) recalls fda
November 15, 2018
FDA is alerting patients and health care professionals to Sandoz’s voluntary recall of one lot – JB8912 – of losartan potassium and hydrochlorothiazide 100mg/25mg tablets, that contain losartan, an angiotensin II receptor blocker (ARB), and hydrochlorothi

Previous page 1 2 3 4 5 6 7 8 Next page